Therapeutic targets for urinary incontinence

Drugs of the Future

Volumn 33, Issue 5, 2008, Pages 455-462

  Sorbera, L A ^a   Bozzo, J ^a   Rosa, E ^a   Dulsat, C ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; AV 608; BESIPIRDINE; CENTRAL NERVOUS SYSTEM AGENTS; CLENBUTEROL; DARIFENACIN; DULOXETINE; EP 0748807; FE 106483; FESOTERODINE; FR 2769914; GRC 6211; IMIDAFENACIN; JP 2002114684; JP 2004123649; JP 2005225845; JP 2005239578; JP 2006306746; JP 205289890; KUC 7483; MIRABEGRON; MN 246; NAFTOPIDIL; ONO 8539; ONO 8569; OXYBUTYNIN; PROPIVERINE; PSD 503; RO 3202904; RO 32029704; SOLABEGRON; SOLIFENACIN; SOU 003; SSR 240600; SVT 40776; TA 5538; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; URINARY TRACT AGENT; US 2005154020; US 2005154022; US 2007270436; US 6693136; VARDENAFIL; WO 1993003725; WO 1993017007; WO 1997017345; WO 1998004546; WO 1998043942; WO 1999006383; WO 1999025710; WO 199906382; WO 2000055143; WO 2000078716; WO 2001064671; WO 2002018348; WO 2002044159; WO 2002114684; WO 2003016254; WO 2003097060; WO 2003099765; WO 2003106444; WO 2004004714; WO 2004005257; WO 2004017960; WO 2004031118; WO 2005000356; WO 2005005395; WO 2005005397; WO 2005009469; WO 2005013989; WO 2005039569; WO 2005058790; WO 2005095359; WO 2005108389; WO 2006002051; WO 2006014024; WO 2006072458; WO 2006082872; WO 2006088075; WO 2006103511; WO 2006106421; WO 2006121104; WO 2006121106; WO 2007024593; WO 2007025899; WO 20070328454; WO 2007038209; WO 2007071358; WO 2007072089; WO 2007072090; WO 2007072091; WO 2007072094; WO 2007072095; WO 2007093542; WO 2007113276; WO 2007132841; WO 2008000645; WO 2008007661; WO 2008007664; WO 2008023720;

ACCESS TO INFORMATION; AGING; BLADDER SPHINCTER; CLINICAL TRIAL; DETRUSOR MUSCLE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; HUMAN; MICTURITION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROTRANSMISSION; NOCTURIA; PATHOPHYSIOLOGY; POLLAKISURIA; REVIEW; SMOOTH MUSCLE CONTRACTION; URGE INCONTINENCE; URINE INCONTINENCE;

EID: 45849084694     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.05.1204517     Document Type: Review

References (38)

1. Prous Science Disease Briefings: Urinary Incontinence (online publication). Updated 2008.
2. Norton, P., Brubaker, L. Urinary incontinence in women. Lancet 2006, 367(9504): 57-67.
3. Cheater, F.M., Castleden, C.M. Epidemiology and classification of urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 2000, 14(2): 183-205.
4. Lam, S., Hilas, O. Pharmacologic management of overactive bladder. Clin Interv Aging 2007, 2(3): 337-45.
5. Tubaro, A., Palleschi, G. Overactive bladder: Epidemiology and social impact. Curr Opin Obstet Gynecol 2005, 17(5): 507-11.
6. Wein, A.J. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 2001, 10(1): 65-83.
7. Andersson, K.E. Advances in the pharmacological control of the bladder. Exp Physiol 1999, 84(1): 195-213.
8. Pinggera, G.M., Mitterberger, M., Pallwein, L. et al. α-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008, 101(3): 319-24.
9. Noguchi, Y., Ohtake, A., Suzuki, M., Sasamata, M. In vivo study on the effects of alpha(1)-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Eur J Pharmacol 2008, 580(1-2): 256-61.
10. Sugaya, K., Nishijima, S., Miyazato, M., Ashitomi, K., Hatano, T., Ogawa, Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002, 328(1): 74-6.
11. Chen, Q., Takahashi, S., Zhong, S. et al. Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J Urol 2005, 174(1): 370-4.
12. Hudman, D., Elliott, R.A., Whitaker, P., Terry, T.R., Sandhu, D.P., Norman, R.I. Inhibition of the contractile responses of isolated human and rat bladders by clenbuterol. J Urol 2001, 166(5): 1969-73.
13. Badawi, J.K., Seja, T., Uecelehan, H., Honeck, P., Kwon, S.T., Bross, S., Langbein, S. Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology 2007, 69(4): 785-90.
14. Hicks, A., McCafferty, G.P., Riedel, E. et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007, 323(1): 202-9.
15. Takasu, T., Ukai, M., Sato, S. et al. Effect of (R)-[2-(2- aminothiazol-4-yl)-4′-2-[(2-hydroxy-2-phenylethyl)amino]ethyl] acetanilide (YM178), a novel selective beta3-adrenoceptor ago nist, on bladder function. J Pharmacol Exp Ther 2007, 321(2): 642-7.
16. Anisuzzaman, A.S., Morishima, S., Suzuki, F. et al. Assessment of muscarinic receptor subtypes in human and rat lower urinary tract by tissue segment binding assay. J Pharmacol Sci 2008, 106(2): 271-9.
17. Takayanagi, R., Mizushima, H., Ozeki, T., Yokoyama, H., Iga, T., Yamada, Y. Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. Biol Pharm Bull 2007, 30(7): 1297-300.
18. Hegde, S.S., Mammen, M., Jasper, J.R. Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies. Curr Opin Investig Drugs 2004, 5(1): 40-9.
19. Mukerji, G., Yiangou, Y., Grogono, J., Underwood, J., Agarwal, S.K., Khullar, V., Anand, P. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006, 176(1): 367-73.
20. Kamo, I., Torimoto, K., Chancellor, M.B., de Groat, W.C., Yoshimura, N. Urethral closure mechanisms under sneeze-induced stress condition in rats: A new animal model for evaluation of stress urinary incontinence. Am J Physiol Regul Integr Comp Physiol 2003, 285(2): R356-65.
21. Ruoho, A.E. How the monoamine transporter garden grows. Mol Pharmacol 2005, 68(2): 272-4.
22. Thor, K.B., Kirby, M., Viktrup, L. Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: Scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 2007, 61(8): 1247-8.
23. Jost, W., Marsalek, P. Duloxetine: Mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res 2004, 14(4): 220-7.
24. Filippi, S., Morelli, A., Sandner, P. et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148(3): 1019-29.
25. Rybalkin, S.D., Rybalkina, I.G., Feil, R., Hofmann, F., Beavo, J.A. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 2002, 277(5): 3310-7.
26. Kulkarni, S.K., Patil, C.S. Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 2004, 26(10): 789-99.
27. Schröder, A., Newgreen, D., Andersson, K.E. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J Urol 2004, 172(3): 1166-70.
28. Ikeda, M., Kawatani, M., Maruyama, T., Ishihama, H. Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats. Biomed Res 2006, 27(2): 49-54.
29. Lee, T., Hedlund, P., Newgreen, D., Andersson, K.E. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol 2007, 177(4): 1562-7.
30. Katofiasc, M.A., Nissen, J., Audia, J.E., Thor, K.B. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002, 71(11): 1227-36.
31. Chien, C.T., Yu, H.J., Lin, T.B., Lai, M.K., Hsu, S.M. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am J Physiol Renal Physiol 2003, 284(4): F840-51.
32. Duffy, R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 2004, 9(1): 9-21.
33. Silva, C., Silva, J., Castro, H., Reis, F., Dinis, P., Avelino, A., Cruz, F. Bladder sensory desensitization decreases urinary urgency. BMC Urol 2007, 7: 9-15.
34. Xie, C., Sachs, J.R., Wang, D.H. Inter-dependent regulation of afferent renal nerve activity and renal function: Role of TRPV1, NK1 and CGRP receptors. J Pharmacol Exp Ther 2008, In press.
35. Verbalis, J.G. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002, 29(1): 1-9.
36. Bonilla-Felix, M. Development of water transport in the collecting duct. Am J Physiol Renal Physiol 2004, 287(6): F1093-101.
37. Koh, S.D., Ward, S.M., Dick, G.M. et al. Contribution of delayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle. J Physiol 1999, 515(Pt. 2): 475-87.
38. Thorneloe, K.S., Nelson, M.T. Properties and molecular basis of the mouse urinary bladder voltage-gated K+ current. J Physiol 2003, 549(Pt. 1): 65-74.